The Pharmaceutical Studies Reader

The Pharmaceutical Studies Reader is an engaging examination of this new and growing field, bringing together provocative, multi–disciplinary articles to look at the interplay of medical science, clinical practice, consumerism, and the healthcare marketplace. Ranging far beyond simple discussion of patients, symptoms, and pills, this reader offers important insights into contemporary cultures of health and illness and the social life of pharmaceuticals.

Drawing on anthropological, historical, and sociological research, it delves into the production, circulation, and consumption of pharmaceuticals.  The coverage here is broad and compelling with discussion of topics such as the advent of oral contraceptives, taxonomies of disease, the evolution of prescribing habits, the ethical dimension of pharmaceuticals, clinical trials, and drug production in the age of globalization.  Placing a strong focus on context, this collection exposes readers to a variety of approaches, ideas, and frameworks and provides them with an appreciation and understanding of the complex roles pharmaceuticals play in society today.

Acknowledgements

1. Introduction
     Jeremy Greene and Sergio Sismondo.

Pharmaceutical lives
2. The pharmaceuticalisation of society? A framework for analysis
     Simon J. Williams, Paul Martin and Jonathan Gabe

3. Pharmaceutical witnessing: Drugs for life in an era of direct–to–consumer advertising
     Joseph Dumit,

New drugs, diseases and identities
4. Releasing the flood waters: Diuril and the reshaping of hypertension
     Jeremy Greene

5. Dep®ession and consum tion: Psychopharmaceuticals, branding, and new identity practices
     Nathan Greenslit

6. BiDil: Medicating the intersection of race and heart failure
     Anne Pollock

7. Manufacturing desire: The commodification of female sexual dysfunction
     Jennifer Fishman

Drugs and the circulation of medical knowledge
8. Following the script: How drug reps make friends and influence doctors
     Adriane Fugh–Berman and Shahram Ahari

9. Getting to yes: Corporate power and the creation of a psychopharmaceutical blockbuster 
     Kalman Applbaum

10. Pushing knowledge in the drug industry: Ghost–managed science
     Sergio Sismondo

11. Transcultural medicine: A multi–sited ethnography on the scientific–industrial networking of Korean medicine
     Jongyoung Kim

Political and moral economies of pharmaceutical research
12. Uncommon trajectories: steroid hormones, Mexican peasants, and the search for a wild yam
     Gabriela Soto Laveaga

13. Ready–to–recruit or Ready to consent populations? Informed consent and the limits of subject autonomy
     Jill Fisher

14. Clinical trials offshored: On private sector science and public health
     Adriana Petryna

15. The experimental machinery of global clinical trials: Case studies from India
     Kaushik Sunder Rajan

Intellectual property in local and global markets

16. Intellectual property and public health: Copying of HIV/AIDS drugs by Brazilian public and private pharmaceutical laboratories
     Maurice Cassier and Marilena Correa

17. Global pharmaceutical markets and corporate citizenship: The case of Novartis anti–cancer drug Glivec
     Stefan Ecks

18. Generic medicines and the question of the similar
     Cori Hayden

Sergio Sismondo is Professor of Philosophy and Sociology at Queen s University, Canada. His current work, including a number of recent articles, explores the pharmaceutical industry s development and deployment of clinical research, focusing on intersections of marketing and science. He is the author and co–author of a number of books, including An Introduction to Science and Technology Studies, Second Edition (Wiley Blackwell, 2010) and The Art of Science (2003). He is Editor of the journal Social Studies of Science.

Jeremy A. Greene is Elizabeth Treide and A. McGehee Harvey Chair in the History of Medicine at Johns Hopkins University. His recent work focuses on the ways in which the development and consumption of therapeutics interact with our understandings of what it means to be sick or healthy, normal or abnormal. His broader research interests focus on the history of disease, the history of global health, and the history of the pharmaceutical industry and its interactions with medical research, clinical practice, and public health.  He is the author of Generic: The Unbranding of Modern Medicines (2014) and Prescribing by Numbers: Drugs and the Definition of Disease (2007), as well as co–editor of Prescribed: Writing, Filling, Using, and Abusing the Prescription in Modern America (2012).